Physician profile
Brian Patrick Rutledge
NPI 1245658202
$6,814.91
in general payments reported to CMS, 2019-2025
27 companies · $1,862 in 2025
The $1,862 reported for 2025 was more than what 77% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $794 · 2020: $650 · 2021: $1,019 · 2022: $560 · 2023: $557 · 2024: $1,374 · 2025: $1,862.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,975 · Food and Beverage: $1,818.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,974.58 |
| Food and Beverage | $1,817.67 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Wilson Cook Medical Incorporated | $1,545.68 | 2024-2025 | Fusion |
| Abbvie INC. | $1,167.61 | 2019-2025 | Rinvoq, Mavyret, Linzess |
| Cook Medical LLC | $658.18 | 2024-2025 | Fusion |
| Gilead Sciences, INC. | $638.74 | 2019-2022 | |
| Janssen Biotech, INC. | $457.47 | 2019-2025 | Tremfya |
| Phathom Pharmaceuticals, INC. | $354.80 | 2024-2025 | Voquezna |
| Ambu INC. | $320.03 | 2020-2021 | |
| Intercept Pharmaceuticals, INC. | $281.08 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $249.32 | 2021-2023 | Stelara, Remicade, Tremfya |
| E.R. Squibb & Sons, L.L.C. | $236.83 | 2021-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $198.12 | 2019-2025 | Xifaxan, Trulance |
| Eisai INC. | $124.78 | 2022 | |
| Perspectum Diagnostics LTD | $111.81 | 2023 | Livermultiscan |
| Merit Medical Systems INC | $85.95 | 2025 | Esophyx |
| Endogastric Solutions, INC | $60.72 | 2024 | Esophyx |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $57.68 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $40.61 | 2020-2021 | |
| Qol Medical, LLC | $32.05 | 2021 | |
| Dynavax Technologies Corporation | $30.09 | 2019-2022 | |
| Ipsen Biopharmaceuticals, INC | $28.57 | 2025 | Iqirvo |
| Pfizer INC. | $27.20 | 2019 | |
| Ardelyx, INC. | $24.59 | 2025 | Ibsrela |
| Celgene Corporation | $19.27 | 2023 | Zeposia |
| Micro-Tech Endoscopy USA, INC. | $18.37 | 2023 | Lockado |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.61 | 2020 | |
| Calliditas Therapeutics US INC. | $14.43 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.32 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Rutledge listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.